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We present a case of a 46-year-old manwith an incidental ﬁnding of a right testicular tumor on magnetic
resonance imaging. He received radical orchiectomy, and the pathological report showed a testicular
carcinoid tumor. He has remained in a stable condition 3 years after the operation. Carcinoid tumors of
the testis are extremely rare and account for less than 1% of testicular tumors and carcinoids. A painless
mass or prominent testis enlargement is the most distinctive presentation. Less than 1e3% of patients
demonstrate carcinoid syndrome. Nuclear scintigraphy scan and computed tomography scan have a
diagnostic value in excluding carcinoid from other sites. Radical orchiectomy is the treatment of choice,
and the prognosis is good for localized carcinoid tumors after resection. Adjuvant chemotherapy or
radiotherapy for advanced disease shows only minimal beneﬁts.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Carcinoid tumors, which most frequently occur in the gastroin-
testinal tract, are uncommon. In a report from the Surveillance,
Epidemiology, and End Results (SEER) program of the National Can-
cer Institute database on 11,427 carcinoid patients treated from 1973
to 1997, themajorityof carcinoidswere located in the gastrointestinal
tract (55%) and bronchopulmonary system (30%).1 DeVita2 reported
that testicular carcinoids account for less than 1% of all testicular
tumors and for only 0.2% of all carcinoid tumors.3 Embryologically,
carcinoid tumors may be derived from foregut, midgut, or hindgut,
and the testicular carcinoid tumor has a midgut origin. Testicular
carcinoid tumors are composed of uniform polygonal cells with ﬁne,
granular chromatin; small nucleoli; and scant tomoderate amount of
cytoplasm.4 Herein, we present a case of a primary testicular carci-
noid tumor along with a literature review.
2. Case report
A 46-year-old man presented to our clinic due to a 2 cm right
testicular mass detected incidentally by magnetic resonance im-
aging (MRI) during a health examination (Fig. 1A and B). The tumortment of Surgery, Taipei Vet-
i Road, Beitou District, Taipei
ng).
blished by Elsevier Taiwan LLC. Opwas nontender, ill deﬁned, and ﬁrm in consistency on palpation;
however, the size of his right testis was normal andmeasured about
3 cm  3 cm  2 cm. No inguinal lymphadenopathy was observed.
The patient denied fever or any recent travel. He also denied diar-
rhea, abdominal cramps, nausea, vomiting, hot ﬂushes, or dyspnea.
His hemogram and biochemistry tests were all normal. Tumor
marker tests showed the following: alpha-fetoprotein: 4.49 ng/mL
(normal 0.00e20.00 ng/mL); beta-human chorionic gonadotropin:
0.08 mIU/mL (normal <5 mIU/mL); and lactate dehydrogenase:
197 U/L (normal 131e250 U/L). Scrotal sonography revealed a
heterogeneous echoic nodule 1.9 cm in size in the right testis with
central calciﬁcation and increased vascularity (Fig. 1C and D). Right
radical orchiectomy was performed uneventfully.
Grossly, the tumor was yellowish white, ﬁrm, and 1.9 cm 
1.5 cm  1.2 cm in size. It was conﬁned to the testis, and the tunica
albuginea and epididymis were free of the tumor (Fig. 2). Micro-
scopic examination revealed that the tumor was composed of
uniform cells bearing round nuclei and growing in a festoon- or
ribbon-like arrangement. Fine cytoplasmic granules were seen.
Tumor cells were positive for chromogranin, CD56, and synapto-
physin immunohistochemically, all of which are markers for
neuroendocrine tumors. The tumor was negative for alpha-inhibin
(Fig. 3), which excluded other possible germ cell tumors. No other
teratomatous component was detected in the specimen. A primary
carcinoid tumor was diagnosed. A gastroenterologist was consulted
after the diagnosis was conﬁrmed. Upper gastrointestinal tract pan-
endoscopy was performed, and no tumors were detected.en access under CC BY-NC-ND license.
Fig. 1. (A and B) Preoperative magnetic resonance image showed a T2 hypointense nodule about 2 cm in size, with coarse calciﬁcation being noted in the right testis (arrow). (C and
D) Scrotal sonogram showed a heterogeneous echoic nodule 2 cm in size in the right testis with central calciﬁcation and increased vascularity.
Fig. 2. Yellowish-white, ﬁrm tumor, 1.9 cm  1.5 cm  1.2 cm in size, in the right testis
(arrow).
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phy and scrotal sonography regularly, and no evidence of tumor
recurrence was found 3 years after the operation. Urine 5-
hydroxyindolacetic acid (5-HIAA) level was also checked and
found to be within normal limits.3. Discussion
Testicular carcinoid tumors are very rare. They can be divided
into three groups: primary testicular carcinoid, carcinoid metas-
tasis to the testis, and carcinoid associated with teratoma. Primary
testicular carcinoid is presumed to originate from argentafﬁn or
Kulchitsky cells, or develop from simpliﬁed teratomawithout other
teratomatous elements.5
A painless mass or prominent testis enlargement is the two
most common clinical presentation of a testicular carcinoid. Less
than 1e3% of carcinoid tumors present with carcinoid syndrome, of
which carcinoids with metastasis are the most common.5 A pre-
vious study reported carcinoid syndrome in 50% of carcinoids with
metastasis and in only 5.6% of nonmetastatic carciniods.5 Elevation
of serum serotonin or urine 5-HIAA levels should raise the suspi-
cion of a metastatic carcinoid tumor.
Because these carcinoids are found mostly in the gastrointestinal
tract, especially in the ileum, video capsule endoscopy has been
shown to have value in the staging of carcinoid tumors. Somatostatin
receptor scintigraphy or iodine-131-metaiodobenzylguanidine scin-
tigraphy may also have a diagnostic value in excluding carcinoids
from sites other than the testis.6 These tests along with computed
tomography should be performed to rule out the possibility of other
metastatic carcinoid tumors. Somatostatin scintigraphy scan has
been demonstrated to be superior than computed tomography scan
Fig. 3. Microscopic ﬁndings. Sections show a picture of a carcinoid composed of uniform cells with round nuclei and growing in a festoon- or ribbon-like arrangement under (A)
40 and (B) 100 magniﬁcation (hematoxylin and eosin stain). Fine cytoplasmic granules are seen. Under 100 magniﬁcation, (C) tumor cells were positive for synaptophysin
immunohistochemically and (D) the tumor was negative for alpha-inhibin staining.
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detecting metastatsis.7
Radical orchiectomy is the treatment of choice for localized
testicular carcinoid tumors, and adjuvant therapies including
chemotherapy and radiotherapy have been shown to have less
optimal effects in the treatment of advanced testicular carcinoids.6
Moertel and Hanley8 concluded that chemotherapy for local or
metastatic carcinoids provides only limited beneﬁts. Another treat-
ment choice, such as interferon a, has been reported for all carci-
noids, with a biochemical response rate of 40%, subjective response
rate of 70%, and reduction in tumor size in 20% of patients.6 Higher
dosages did not show obvious beneﬁts in size reduction.6
Postoperative follow-up including history taking, physical ex-
amination, urine 5-HIAA level, chest X-ray, chest and abdominal
computed tomography scans or MRI, and octreotide scintigraphy
should be conducted to rule out extratesticular metastasis.6 Urine
5-HIAA, a metabolite of serotonin, can be measured in a 24-hour
urine sample as a marker for follow-up. The sensitivity of this
test reaches 75%, with speciﬁcity up to 100%.9 However, the results
may be inﬂuenced by the ingestion of certain drugs and foods.
Plasma chromogranin A is another marker that is useful in
detecting neuroendocrine tumors; however, it has higher sensi-
tivity and lower speciﬁcity than 5-HIAA.4 Our patient received
whole-bodyMRI during a health examination and showed no other
problems aside from the testicular tumor; there was no evidence of
recurrence or metastasis after 3 years of follow-up.
The prognosis of a localized testicular carcinoid tumor after
operation isexcellent. In anarticle,Wangetal4 reportedon29casesof
primary testicular carcinoid tumors of the testis. All the 20 patients
with primary testicular typical carcinoid tumor were alive without
recurrence. Zavala-Pompa et al10 reported 57 patients with primary
testicular carcinoid tumor: 43 had pure carcinoid tumor and 14 were
associated with mature teratoma. Six patients developed distant
metastasis, and most of them had larger tumors of pure carcinoid
type.However, a long-termfollow-upwassuggested, as isolatedcases
of testicular carcinoids have been reported to exhibit an aggressivemetastatic course following a prolonged disease-free interval .4 Our
patient received whole-body MRI during a health examination and
showednoother problems aside from the testicular tumor; therewas
no evidence of recurrence or metastasis after 3 years of follow-up.
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